bit.bio raises $25m to expand its human-cell research models

Discovering a possible medicine is only the beginning. Researchers still need biological systems in which to test it.

What happened

Cambridge-based bit.bio secured $25 million in Series D funding, with backing including existing investor M&G Investments and Abcam founder Jonathan Milner.

The company produces human-cell models for research. Its portfolio spans more than 50 cell types, including models of the heart, liver and central nervous system. Funding will support additional cell types and wider customer access.

Why it matters

Research teams need consistent experimental material to compare results across studies. A supplier that can produce defined human cells repeatedly and at useful scale addresses a practical bottleneck in laboratory work.

The bigger picture

The business sits in the tools supporting drug discovery, rather than depending on the approval of one medicine. Demand figures remain company disclosures, and the availability of human-cell models does not establish that a particular experiment will predict clinical outcomes.